key: cord-0727399-4wxplbyl
authors: Bemtgen, Xavier; Klingel, Karin; Hufnagel, Markus; Janda, Ales; Bode, Christoph; Staudacher, Dawid L.; Supady, Alexander; Jandova, Ilona
title: Case Report: Lymphohistiocytic Myocarditis With Severe Cardiogenic Shock Requiring Mechanical Cardiocirculatory Support in Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection
date: 2021-09-09
journal: Front Cardiovasc Med
DOI: 10.3389/fcvm.2021.716198
sha: 522f17926370137bc99afa775a0a0836e737a6b2
doc_id: 727399
cord_uid: 4wxplbyl

Multisystem Inflammatory Syndrome (MIS) is a novel hyperinflammatory syndrome associated with SARS-CoV-2 infection. It predominantly affects children (MIS-C) a few weeks after a usually asymptomatic SARS-CoV-2 infection and is only rarely seen in adults above 21 years (MIS-A). Only scarce data on histological findings in both pediatric and adult patients has been published so far. An 18-year-old male patient was admitted to hospital in a febrile state, which progressed to severe cardiogenic shock and multi-organ failure requiring extracorporeal life support. Myocardial biopsy revealed small vessel-associated immune cell infiltrates. Diagnosis of MIS-C was made after ruling out all potential differential diagnosis. Use of immunosuppressive treatment with steroids, interleukin-1 blockade and high-dose intravenous immunoglobulins resulted in the patient's full recovery. Multisystem Inflammatory Syndrome (MIS) is a new differential diagnosis of cardiac dysfunction in pediatric and adult patients. The lack of myocardial necrosis differentiates the disease from other viral myocarditis and offers an explanation for the fast response to immunomodulatory therapy and the favorable prognosis. The preceding SARS-CoV-2 infection might only have been mildly symptomatic or even asymptomatic.

Coronavirus disease 2019 (COVID- 19) with respiratory failure is the primary complication of an infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults. Here, diagnosis and treatment is progressively better understood (1) . In pediatric patients however, a novel hyperinflammation syndrome called Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious pathology caused by a SARS-CoV-2 infection (2) . The awareness and knowledge on this hyperinflammation syndrome are steadily growing among pediatricians, but the more uncommon adult variant of this syndrome, Multisystem Inflammatory Syndrome in Adults (MIS-A), is widely unknown in adult medicine. The threshold between the pediatric and the adult variant is 21 years as defined by the CDC (3) . Only scarce data on histological findings in both pediatric and adult patients has been published so far.

Here, we report the case of a young adult with severe cardiogenic shock diagnosed with severe MIS-C backed by myocardial biopsy and rapid recovery following initiation of immunosuppressive treatment.

An 18-year-old male patient presented to the emergency department with hyperpyrexia (42 • C), chills and tachycardia. Physical examination and chest X-ray revealed no pathological findings. Laboratory tests showed elevated C-reactive protein (CRP; 105.9 mg/l, reference range <5 mg/l) as well as interleukin 6 serum levels (IL-6; 128 pg/ml, reference range <7 pg/ml), but only modestly elevated procalcitonin (PCT; 0.12 ng/ml, reference range <0.05 ng/ml) (Figure 1) . The patient was admitted to a standard care ward and an empiric antibiotic therapy was initiated.

The patient's medical history was unremarkable. Approximately 2 months prior to admission, the patient was exposed to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and went into quarantine. A few days after this exposure, he complained he had lost his sense of smell, but he experienced no other symptoms. Neither during his quarantine nor after his initial admission to the hospital was an active SARS-CoV-2 infection ever proven, despite repeated nasopharyngeal swabs.

Following admission, the patient's condition steadily deteriorated. After 3 days he was transferred to the intensive care unit (ICU) due to arterial hypotension with suspected septic shock. Initially, intravenous fluid resuscitation and a low rate of noradrenaline (0.01 µg/kg/min) were sufficient to stabilize the patient's blood pressure. A generalized rash affecting the abdomen and all limbs occurred. On day 4 following hospital admission, transthoracic echocardiography revealed a severely impaired left ventricular cardiac function (left ventricular ejection fraction, LVEF, 25%, Supplementary Video 1). No relevant ECG pathologies were seen beside sinustachycardia. At that time, Pulse Contour Cardiac Output (PiCCO; Getinge, Rastatt, Germany) measurement confirmed marginal cardiac output of 4.4 l/min (reference range: 4-8 l/min). Computed tomography showed enlarged abdominal lymph nodes, wall thickening of the colon and polyserositis with pericardial and pleural effusions and ascites. Respiratory failure due to pulmonary edema required non-invasive ventilation (NIV).

Subsequently, on day 4 after hospital admission, liver and renal failure and massive systemic inflammatory response became evident (Figure 1 ). The rheumatology workup (anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), anti-neutrophil cytoplasmic antibodies (ANCA), anti-phospholipid antibodies, complement) were unremarkable. Microbiological investigation only revealed positive SARS-CoV-2 serology (anti-S1 and anti-N antibodies).

Four days after initial hospital admission, the patient was transferred to our hospital, a tertiary care center in Freiburg, Germany. Upon admission, levosimendan infusion was started. The following day, endomyocardial biopsy (EMB) was performed. Signs of hypoperfusion end organ failure persisted (elevated lactate, renal function, Figure 1 ). For this reason, a percutaneous ventricular assist device (Impella R , Abiomed, Danvers, NJ, United States of America) was implanted. Subsequently, cardiac output improved from 3.6 to 4.9 l/min and pulmonary capillary wedge pressure decreased from 26 to 21 mmHg.

However, due to both progressive hypoxemia under NIV with a required fraction of inspired oxygen (FiO 2 ) of up to 100% and to worsening neurological symptoms (sopor), invasive mechanical ventilation was indicated. Within just a few hours after endotracheal intubation, additional venoarterial extracorporeal membrane oxygenation (V-A ECMO) support was required, because of worsening hypoperfusion and severe end-organ failure (Figure 1) .

EMB showed a significant infiltration of immune cells into the heart. Especially CD68+ macrophages but also CD3+ T cells were found to be located primarily around small vessels within the myocardium, as shown by immunohistochemical stainings (see circle). Masson Trichrome and HE stainings further demonstrated the presence of perivascular fibrosis in serial tissue sections, but no myocyte necrosis (Figures 2A-D In addition, qRT-PCR did not detect SARS-CoV-2 RNA in the myocardium.

Following interdisciplinary discussion (pediatrics, rheumatology, cardiology, and infectious disease), Multisystem Inflammatory Syndrome in children (MIS-C) following preceding SARS-CoV-2 infection was diagnosed and immunosuppressive therapy including high-dose intravenous immunoglobulin (IVIG), dexamethasone and IL-1-blockade (anakinra) was initiated (Figure 1) . Clinical and laboratory parameters improved within 3 days and 1 day, respectively (Figure 1) . As cardiac function recovered, this enabled discontinuation of extracorporeal cardiocirculatory support (V-A ECMO, Impella R ) on day seven after initiation. Cardiac necrosis parameters were only moderately elevated during the shock phase (max. TroponinT 341 ng/L, ref <14 ng/L; CK-MB max 54 U/L, ref < 24 U/L) indicating only a minor myocardial damage has occurred. Cardiac function did indeed fully recover (Supplementary Video 2) . Renal function only was able to fully recover after 30 days to full recovery. The patient was able to be discharged 32 days after initial hospital admission.

Early during the SARS-CoV-2 pandemic, a novel hyperinflammatory syndrome was described. Initially, only pediatric cases were identified with symptoms and clinical findings, which in many respects resembled features of Kawasaki disease and Toxic Shock Syndrome (4, 5) . Two synonymic terms-Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric Inflammatory Multisystem Syndrome temporarily associated with SARS-CoV-2 (PIMS-TS)-were established (3, 6, 7) . Later, a similar syndrome was reported in adults (MIS-A) (8, 9) .

Our patient fulfilled the diagnostic criteria of MIS-C with fever, rash, lymphadenopathy, shock, myocardial injury, colitis, and positive SARS-CoV-2 serology, as well as severe inflammatory response. For this reason, immunomodulatory therapy based on clinical recommendations of the American College of Rheumatology (ACR) was initiated (3) .

ACR recommends steroid treatment with methylprednisolone (20-30 mg/kg a day, for 1-3 days up to 1 g per day followed by tapering doses−2 mg/kg a day, maximum 60 mg a day); high-dose intravenous immune globulin therapy (2 g/kg a dose) in moderate to severe cases; and cytokine receptor (IL-1 or IL-6) blockade (3).

As with myocardial involvement following other viral infections, cardiac injury in MIS-C may occur either due to direct cardiac invasion by the virus (10-13) or else following accompanying cytokine storm (2) . Since EMB is only rarely performed, the reported cases of myocardial injury in the context of the SARS-CoV-2 infection are largely based upon clinical symptoms, laboratory results and imaging findings (e.g., electroand echocardiography, magnetic resonance). Arrhythmias, decreased LVEF and high prevalence of cardiogenic shock were reported (14) . Histopathological investigations of EMB in patients with COVID-19 revealed multi-focal lymphocytic and interstitial macrophage infiltrates (15) without substantial myocyte necrosis. Despite the fact that SARS-CoV-2 can infect macrophages but also myocytes (16) , this virus is obviously not cytolytic as e.g., coxsackievirus B3 (17) . So far, the exact molecular mechanisms by which the infiltration of many macrophages and less T cells are induced in MIS patients are not known. It is likely that SARS-CoV-2 rather induces an inflammatory response by cytokine release, thus resulting in a kind of indirect myocardial injury (18) . Further investigations are required to investigate why in MIS patients but not in other patients with myocardial SARS-CoV-2 infections the inflammation is associated with the vessels (19) . It has to be discussed whether the presence of extensive perivascular lympho-histiocytic infiltrates without myocyte necrosis may explain the rapid response to immunosuppressive therapy in our patient. This is similar to other reported cases (9, 14, 20) .

Even following asymptomatic SARS-CoV-2 infection, children and young adults may develop severe Multisystem Inflammatory Syndrome in Children or Adults (MIS-C/A). In our case report, myocardial involvement (verified by endomyocardial biopsy) caused severe cardiogenic shock requiring medical as well as mechanical cardiocirculatory support. Early immunomodulatory treatment with glucocorticoids, intravenous immunoglobulin and cytokine receptor blockade helped control symptoms and interrupt uncontrolled inflammatory response. The patient's cardiac function recovered after 7 days on mechanical cardiocirculatory support with Impella R and V-A ECMO. Prompt diagnosis of MIS-C is critical, as swift use of intense immunosuppressive therapy may lead to a better prognosis for the patient. Therefore, we advise critical care clinicians to consider this differential diagnosis early on when confronted with patients suffering from severe inflammatory response and impaired cardiac function.

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

XB, AS, and IJ conceived and designed the case report, collected the data, and wrote the manuscript. KK contributed to the pathology diagnosis. IJ, MH, DS, and AJ contributed to the clinical diagnosis. CB supervised the conception, analysis, design of the work, and manuscript drafting. All authors critically revised the manuscript for important intellectual content and provided approval of the final version. 

A sincere thank you to Natalie Diffloth for her diligent proofreading of this paper.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm. 2021.716198/full#supplementary-material

COVID-19: a review of therapeutic strategies and vaccine candidates

Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)

American College of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2

Hyperinflammatory shock in children during COVID-19 pandemic

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Multisystem inflammatory syndrome in U.S. children and adolescents

Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection -United Kingdom and United States

Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies

Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe

Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study

SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes

Lethal enterovirus myocarditis in a patient with granulomatosis with polyangiitis following rituximab and high-dose steroid therapy

Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases

COVID-19 and myocarditis: findings from cardiac magnetic resonance imaging and endomyocardial biopsies

Delayed-onset myocarditis following COVID-19

Supplementary Video 1 | Apical 4 chamber view at admission. Severely impaired left ventricular function seen directly after admission to our hospital.Supplementary Video 2 | Apical 4 Chamber view after recovery. Fully recovered function seen 2 days after V-A ECMO and Impella ® explantation.

AS reports research grants and lecture fees from CytoSorbents and lecture fees from Abiomed, both outside the submitted work.The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.